Donald J. Kellerman

1.3k total citations
29 papers, 1.1k citations indexed

About

Donald J. Kellerman is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Donald J. Kellerman has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 11 papers in Physiology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Donald J. Kellerman's work include Asthma and respiratory diseases (11 papers), Inhalation and Respiratory Drug Delivery (9 papers) and Respiratory and Cough-Related Research (7 papers). Donald J. Kellerman is often cited by papers focused on Asthma and respiratory diseases (11 papers), Inhalation and Respiratory Drug Delivery (9 papers) and Respiratory and Cough-Related Research (7 papers). Donald J. Kellerman collaborates with scholars based in United States, United Kingdom and Germany. Donald J. Kellerman's co-authors include Amy Schaberg, Michael Noonan, Kelly K. Nichols, Paul Chervinsky, Rex N. Brogden, David S. Pearlman, Patrick Koch, William J. Jusko, Benjamin R. Yerxa and Howard Boltansky and has published in prestigious journals such as Neurology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Donald J. Kellerman

29 papers receiving 979 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald J. Kellerman United States 14 541 527 171 110 94 29 1.1k
M J Cushley United Kingdom 14 636 1.2× 504 1.0× 25 0.1× 107 1.0× 199 2.1× 20 984
Isabelle Dumont Canada 19 212 0.4× 75 0.1× 142 0.8× 238 2.2× 10 0.1× 52 986
Zoubir Djerada France 17 42 0.1× 54 0.1× 59 0.3× 194 1.8× 81 0.9× 91 916
Hui Jin China 21 275 0.5× 72 0.1× 118 0.7× 207 1.9× 12 0.1× 73 1.1k
Andersson Ke Sweden 20 152 0.3× 117 0.2× 74 0.4× 147 1.3× 9 0.1× 48 1.1k
Eckhard Leifke United States 18 148 0.3× 173 0.3× 140 0.8× 543 4.9× 9 0.1× 44 1.7k
S. Lindgren Sweden 16 197 0.4× 50 0.1× 17 0.1× 285 2.6× 13 0.1× 38 696
Andrea L. Harabin United States 15 180 0.3× 600 1.1× 51 0.3× 228 2.1× 4 0.0× 26 1.3k
Paul Chervinsky United States 31 3.1k 5.7× 2.3k 4.4× 61 0.4× 145 1.3× 3 0.0× 88 3.5k
Edward W. Lipkin United States 21 442 0.8× 73 0.1× 135 0.8× 231 2.1× 5 0.1× 46 1.3k

Countries citing papers authored by Donald J. Kellerman

Since Specialization
Citations

This map shows the geographic impact of Donald J. Kellerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald J. Kellerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald J. Kellerman more than expected).

Fields of papers citing papers by Donald J. Kellerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald J. Kellerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald J. Kellerman. The network helps show where Donald J. Kellerman may publish in the future.

Co-authorship network of co-authors of Donald J. Kellerman

This figure shows the co-authorship network connecting the top 25 collaborators of Donald J. Kellerman. A scholar is included among the top collaborators of Donald J. Kellerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald J. Kellerman. Donald J. Kellerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kellerman, Donald J., et al.. (2012). Nausea Associated with Dihydroergotamine Is a Function of Maximum Concentration and Not Route of Administration (P03.238). Neurology. 78(Meeting Abstracts 1). P03.238–P03.238. 2 indexed citations
3.
Kellerman, Donald J., et al.. (2008). Denufosol: A review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulmonary Pharmacology & Therapeutics. 21(4). 600–607. 73 indexed citations
4.
Kellerman, Donald J.. (2008). The Use of Oral Antihistamines (OA) in Moderate to Severe Dry Eye Patients. Journal of Allergy and Clinical Immunology. 121(2). S131–S131. 1 indexed citations
5.
Johnson, Fred L., José L. Boyer, Philip T. Leese, et al.. (2007). Rapid and reversible modulation of platelet function in man by a novel P2Y12ADP-receptor antagonist, INS50589. Platelets. 18(5). 346–356. 13 indexed citations
6.
Moss, Richard B., Alison Heald, Dana Mathews, et al.. (2005). 97 INS37217 (denufosol tetrasodium) inhalation solution: Phase 1 & 2 clinical experience. Journal of Cystic Fibrosis. 4. S27–S27. 1 indexed citations
7.
Nichols, Kelly K., et al.. (2004). Diquafosol tetrasodium: a novel dry eye therapy. Expert Opinion on Investigational Drugs. 13(1). 47–54. 76 indexed citations
8.
Tauber, Joseph, William F. Davitt, Kelly K. Nichols, et al.. (2004). Double-Masked, Placebo-Controlled Safety and Efficacy Trial of Diquafosol Tetrasodium (INS365) Ophthalmic Solution for the Treatment of Dry Eye. Cornea. 23(8). 784–792. 130 indexed citations
9.
Sall, Kenneth, et al.. (2002). Presenting Symptoms from Diary Cards for Dry Eye Clinical Trial Subjects. 43(13). 3067–3067. 3 indexed citations
10.
Kellerman, Donald J.. (2002). P2Y2 Receptor Agonists. CHEST Journal. 121(5). 201S–205S. 32 indexed citations
11.
Kellerman, Donald J., et al.. (1999). Pharmacokinetics and Pharmacodynamics of Cumulative Single Doses of Inhaled Salbutamol Enantiomers in Asthmatic Subjects. Pulmonary Pharmacology & Therapeutics. 12(6). 353–362. 56 indexed citations
12.
Li, James T.C., Linda B. Ford, Paul Chervinsky, et al.. (1999). Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. Journal of Allergy and Clinical Immunology. 103(6). 1062–1068. 63 indexed citations
13.
14.
Kellerman, Donald J., et al.. (1998). Pharmacokinetic and Pharmacodynamic Characteristics and Safety of Inhaled Albuterol Enantiomers in Healthy Volunteers. The Journal of Clinical Pharmacology. 38(12). 1096–1106. 40 indexed citations
15.
Lawrence, Michael B., et al.. (1997). Efficacy of Inhaled Fluticasone Propionate in Asthma Results from Topical and Not from Systemic Activity. American Journal of Respiratory and Critical Care Medicine. 156(3). 744–751. 58 indexed citations
16.
Pearlman, David S., Michael Noonan, Donald P. Tashkin, et al.. (1997). Comparative Efficacy and Safety of Twice Daily Fluticasone Propionate Powder Versus Placebo in the Treatment of Moderate Asthma. Annals of Allergy Asthma & Immunology. 78(4). 356–362. 48 indexed citations
17.
Wasserman, Stephen I., Gary N. Gross, William F. Schoenwetter, et al.. (1996). A 12-Week Dose-Ranging Study of Fluticasone Propionate Powder in the Treatment of Asthma. Journal of Asthma. 33(4). 265–274. 59 indexed citations
18.
Okamoto, L, Michael Noonan, Bennett P. deBoisblanc, & Donald J. Kellerman. (1996). Fluticasone Propionate Improves Quality of Life in Patients with Asthma Requiring Oral Corticosteroids. Annals of Allergy Asthma & Immunology. 76(5). 455–461. 60 indexed citations
19.
Noonan, Michael, Paul Chervinsky, William W. Busse, et al.. (1995). Fluticasone Propionate Reduces Oral Prednisone Use While It Improves Asthma Control and Quality of Life. American Journal of Respiratory and Critical Care Medicine. 152(5). 1467–1473. 146 indexed citations
20.
Thadani, Udho & Donald J. Kellerman. (1983). Interaction of indomethacin and nitroglycerin on hemodynamics and exercise tolerance in patients with angina pectoris.. PubMed. 72 Suppl 3. 35–9. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M J Cushley Breakdown of academic impact, for papers by Isabelle Dumont Breakdown of academic impact, for papers by Zoubir Djerada Breakdown of academic impact, for papers by Hui Jin Breakdown of academic impact, for papers by Andersson Ke Breakdown of academic impact, for papers by Eckhard Leifke Breakdown of academic impact, for papers by S. Lindgren Breakdown of academic impact, for papers by Andrea L. Harabin Breakdown of academic impact, for papers by Paul Chervinsky Breakdown of academic impact, for papers by Edward W. Lipkin
Rankless by CCL
2026